The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00626860
Recruitment Status :
First Posted : February 29, 2008
Last Update Posted : March 28, 2017
Beth Israel Deaconess Medical Center
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
David Avigan, Beth Israel Deaconess Medical Center
This study aims to determine if the vacccine can be used safely in patients with advanced melanoma (cancer of the pigment cells) and whether the cells in this vaccine are capabale of producing immune responses against your own cancer.
Condition or disease
Biological: DC/tumor fusion vaccine
Phase 1Phase 2
To assess the toxicity associated with vaccination of melanoma patients with dendritic cell (DC)/tumor fusions. To determine if cellular and humoral immunity can be induced by serial vaccination with DC/tumor fusions cells. To determine if vaccination DC/tumor fusions results in a tumor response.
To assess the toxicity, cellular and humoral immunity and tumor response in patient with melanoma receiving the DC/tumor fusion vaccine [ Time Frame: screening/baseline, treatment period and follow-up ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
patients with confirmed diagnoses of disseminated melanoma, with measurable and clearly progressive metastatic involevment
Patients must be at least 18 years old
Patients must have ECOG performance status 0-1 with greater than 9 week life expectancy
Those patients with the following accessible tumor will be eligible: soft tissue, bone marrow or visceral lesions; Skin or superficial soft tissue, or lymph nodes amenable to resection under local anesthesia; Patients who require surgical procedures that are not considered significantly invasive but may require general anesthesia, such as thorascopic biopsy, laparascopic biopsy or mediastinal node biopsy may potentially be eligible; Malignant ascites or pleural effusion; Patients requiring major surgical intervention will be considered ineligible. Patients scheduled to undergo tumor resection for independent diagnostic or therapeutic indications may have tumor collected for the purposes of this study.
Women of childbearing age must have a negative pregnancy test and adequate contraception method(s) must be documented
All patients must be informed of the investigational nature of this study and must give written informed consent in accordance with institutional and federal guidelines
Patients must not have received other immunotherapy treatment in the past four weeks prior to study entry
Patients must not have received chemotherapy for three weeks prior to the first vaccination
Patients must be without evidence of active CNS disease
Patients must not have clinically significant autoimmune disease
Patients must be HIV negative
Patients must not have serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure
Patients requiring corticosteroids for either melanoma related or co-morbid illness